Bristol Myers Squibb's Abecma Becomes First CAR T Approved For Use In Earlier Lines Of Therapy For Patients With Relapsed Or Refractory Multiple Myeloma In Japan
Portfolio Pulse from Benzinga Newsdesk
Bristol Myers Squibb's Abecma, a CAR T cell immunotherapy, has been approved in Japan for use in earlier lines of therapy for patients with relapsed or refractory multiple myeloma (RRMM) who have received at least two prior therapies. This makes Abecma the first CAR T therapy approved for such use in Japan. The approval is based on the KarMMa-3 study, which showed Abecma significantly increased median progression-free survival compared to standard regimens. The results will be presented at the American Society of Hematology Annual Meeting in San Diego.
December 06, 2023 | 6:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's Abecma has been approved in Japan for earlier treatment of RRMM, potentially increasing its market and usage. This approval could positively impact BMY's revenue from Abecma in the Japanese market.
The approval of Abecma in Japan for earlier lines of therapy expands its potential usage and market share, which is likely to have a positive impact on Bristol Myers Squibb's revenue from this product. The strong trial results and the first-mover advantage in this new indication could lead to increased sales and a positive investor sentiment in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100